We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.80 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.75 | 0.85 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 34k | -1.94M | -0.0071 | -0.35 | 2.2M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.80 | GBX |
Evgen Pharma (EVG) Share Charts1 Year Evgen Pharma Chart |
|
1 Month Evgen Pharma Chart |
Intraday Evgen Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 29/4/2024 | 09:24 | EVGEN PHARMA - 2022 BREAST CANCER TREATMENT SFX-01 | 2,852 |
| 02/11/2022 | 19:21 | EVGEN PHARMA - Well funded - A respected BOD - A rising Star | 214 |
| 10/10/2022 | 18:41 | Evgen Pharma PLC | 48 |
| 10/10/2022 | 11:33 | Evgen Guild thread | 151 |
| 10/10/2022 | 07:20 | Evgen Pharma: Undoubted Transformational Upside Potential | 2,433 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 16/6/2025 09:20 by Evgen Pharma Daily Update Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p.Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £687,220. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.35. This morning EVG shares opened at - |
Posted at 19/2/2024 11:25 by manual dexterity RNS Number : 6330DEvgen Pharma PLC 19 February 2024 Evgen Pharma plc ("Evgen" or "the Company" or "the Group") Positive update on SFX-01 in vitro Glioblastoma (GBM) studies Further evidence of SFX-01 activity as seen at other academic centres Alderley Park, UK - 19 February 2024: Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces that the laboratory of Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Centre has observed continuing activity of SFX-01 in GBM cells. The in vitro studies, which are supported by a grant awarded by the KWF Dutch Cancer Society for a €1.1m project, are designed to investigate the activity of SFX-01 in preclinical GBM models. This work is to be followed by administration of SFX-01 to patients with GBM in a clinical Investigator Sponsored Study (ISS). The scientific collaboration, which commenced in October 2023, will run for three years, generating data continuously throughout the period. According to the lead investigator, Dr Marjolein Geurts, neuro-oncologist at Erasmus University Medical Center, "We have seen continued evidence of biological activity in patient-derived glioblastoma tissue." Dr Huw Jones, CEO of Evgen Pharma said: "These early data triangulate with those seen by our other academic collaborators in Abbruzzo, Italy and Auckland, New Zealand. This is another major academic group observing these effects in tissue derived from a different population of GBM patients which gives us further confidence of SFX-01's potential as a therapeutic option for glioblastoma, a disease with very high unmet medical needs which is devastating for patients and their carers." -Ends- Enquiries Evgen Pharma plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, CBO +44 207 457 2020 enquiries@evgen.com Cavendish Capital Markets (NOMAD and Broker) Geoff Nash / Teddy Whiley (Corporate Finance) Nigel Birks (ECM) +44 20 7220 0500 Instinctif Partners Melanie Toyne-Sewell / Jack Kincade +44 207 457 2020 Evgen@Instinctif.co |
Posted at 09/2/2024 11:09 by tomboyb 09/02/2024 11:01amRNS Regulatory News RNS Number : 5388C Evgen Pharma PLC 09 February 2024 Evgen Pharma plc ("Evgen" or "the Company" or "the Group") Notice of Dispute lodged with Stalicla SA Alderley Park, UK - 9 February 2024: Evgen Pharma plc (AIM: EVG, Evgen), a clinical stage drug development company developing sulforaphane-based medicines, has issued a notice of dispute with Stalicla SA (Stalicla) its partner in autism spectrum disorder (ASD) and other neurodevelopmental disorders. In October 2022, Evgen licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla for up to $160.5m in milestone payments. An initial $0.5m was paid upfront with the next anticipated payment of $0.5m due on completion of the Evgen-sponsored human volunteer Phase 1 study. The Phase 1b human volunteer study was completed and the clinical study report finalised in August 2023. As announced on 16 January 2024, Evgen has been working with Stalicla on delivery of the associated milestone payment. The board of Evgen believes that the Company has met the terms required to satisfy the milestone, according to the License Agreement, and thus the payment is now due. In order to effect the payment, Evgen has taken the decision to formally implement the dispute resolution process detailed in the License Agreement, the first step of which is the issuance of a dispute notice. As stated in the half year results in October 2023, Evgen has not anticipated any milestone payments from Stalicla in its financial forecasting and its cash runway remains unchanged. Dr Huw Jones, Evgen CEO commented: "We continue to work closely with our partner for a quick and amicable resolution of the current dispute. We have taken a prudent approach of not recognising any milestone income in our cash projections and therefore the cash position remains unchanged. In the meantime we continue at pace with our internal programmes in oncology which are proceeding to plan." |
Posted at 21/1/2024 03:22 by w t tutte I do not understand the obsession with who is selling and why. It provides no new information. as anyone buying or selling has no better understanding of the situation than you or me.The only thing that matters here, at least as far an existing shareholders are concerned, is do Stalicla proceed to Phase II. EVG have a comfortable 12 months of cash which is sufficient time for this to play out or not. Stalicla proceed, cash runway is extended and value inflection point of going in to phase II gets baked in to valuation. Further cash is raised at much higher share price and time is bought for progress, in other indications, to play in to valuation. (Best Outcome) Stalicla do not proceed. EVG has limited cash remaining and no line of sight to any milestone payments. Share price crashes (yes, even from here) they raise a small amount to limp on but existing shareholders are wiped out. (Worst Outcome) The outlier that upsets this binary analysis is an unquantifiable event, which would skew positively and that would be that they conclude a deal in another indication that comes with a bit of cash. So how do you try to determine if Stalicla are likely to proceed or not ? Well this week in their Series B press release and now having most of the data they need to make an evaluation they have stated that they are continuing their work on STX01 Package. This would have been an easy point to drop the program, should they have wanted to. On the negative side it suggests, at this stage, they might not be looking to take it in to Phase II with their own cash. They may already have a partner lined up but at very least, it would suggest that they think the asset is capable of being partnered. The cost of taking this in to Phase II, including the milestone payment is likely to be @US$20 million. Which is more than they raised, but of course nothing to stop them coming back to raise for STX01, note in their press release that Stalicla refer to this raise as the FIRST round of the Series B. A couple of interesting things to note from linkedin, that may or may not be significant. 1) The New CFO seems to be based in Switzerland, as is Stalicla. Coincidence ? 2) I could not find a single EVG employee, including Huw, who liked the Stalicla Series B announcement. Suggests to me they do not see this event as directly impactful to EVG. So where do I sit, given the share price and the approach of Stalicla and also how hot the CNS sector is right now. I lean (60/40) towards STX01 moving in to phase II. I think this is most likely to happen via Staliclia entering in to a partnership (which I suspect is already lined up), however there is a sneaking suspicion that Staliclia is on a near term IPO track and may raise again in the near term with one of the use of proceeds to be taking STX01 in to Phase II. Will be looking to buy a few here but will be scaling and pricing it like a 12 month option (cash runway until they have to raise) and not an investment. |
Posted at 19/1/2024 21:00 by clocktower Post 2600 is just basically what Wololol has already informed everyone on the thread, and the rest of the post is just fluff, as they could never answer the questions about the future or why or where AXA is until they receive or pass on this information in a RNS, or AXA delivers it straight to market.Monday should tell us if they have reduced their stake or if the stock came from elsewhere but I think that 99% of us are now in agreement that following the last non-RNS was clarified by Wololol, that we are all positive once again, and those that were out or with a reduced holding are now back in and if not fully topped up are pretty well invested here, and are waiting for a lot of positive news in the coming months. I think we are also agreed that the overhang is gone and any reasonable level of buying even without news should quickly send the share price back over 2p/2.5p and with news it could easily go back towards 5p and if there is a string of good news, it’s anyone’s guess. I am however surprised that they left it to individuals to effectively post the clarification of their news, rather than doing it themselves, so to be sure the whole market is aware, and not just those that follow threads on various media/financial websites, ensuring more investors we’re likely to become holders or traders. Hopefully they do not make such a botch of any future positive news. Still, it’s time they bought in as well which would take the share price well up by itself imo. I still have a sneaking belief that someone is building a huge stake with a view to taking it over. The reason for this is the millions that AXA sold when they last advised the reduction of stake at around 1.60p we had no RNS about any new large holder. I also don’t think AXA have reduced their stake, I think others have made an agreement to facilitate the deal but we shall see shortly as I might be completely wrong. |
Posted at 19/1/2024 18:55 by xxproinvestorxx Posting my message from the LSE BBI contacted shareholder relations after the release of the last RNS with a few quires for the bod and received an email back from Huw. Unfortunately, and as expected, he could not comment on a few of my questions, but he answered the ones he could. A few of these questions I wanted clarification due to the lies, miss-information and fear mongering spread by a few posters here (Kingalf and CJ). There have been suggestions from these un-invested posters that due to the wording of the RNS, the company no longer anticipates receiving up to $5.5m in 2024 from the Stalicla partnership. Could you please confirm that the bod remains confident in the anticipation of receiving these milestone payments from Stalicla before year end (and the application of IND from the FDA). “The language used in Tuesday’s Reach was consistent with our previous guidance on cash runway which we have always stated does not account for receipt of milestone payments. We do not incorporate milestone payments into the forecast due to their event-based nature, it would be misleading to do so when success and timing cannot be unequivocally guaranteed, this is accepted risk management practice, as well as a requirement from our auditors.” “The milestone is event driven rather than time driven and I’m afraid we can’t comment further at this time.” I was under the impression that the company was due to receive $0.5m on completion of the human volunteer Phase 1/1b study. As this study was completed last year, has the company received the money? If not, when is this expected to be paid (I assume imminently due to the Stalicla cash raise?) and am I correct to assume that this will extend our cash runway as it would not have been included in the bod’s figures? “The Phase 1b milestone invoice of $500k was reflected in the half-year results released on 31st October 2023. We continue to work with our partner to deliver the payment and will provide updates when we have news to share. Future milestones are based on development activity the timeline of which is managed by Stalicla. As for Stalicla’s future fundraise activities, due to confidentiality reasons, we are not able to share further information on our partners fundraising activity over and above what they have already stated publicly.” Several posters keep making refence to an impeding cash raise, from the issuing of a large number of shares. This includes suggesting that the bod will attempt to raise $10m from the issuing of over 660m shares, decimating existing shareholder value. While I understand a cash raise cannot be ruled out, can you confirm the bod’s intentions on cash raises and if they would/would not attempt to raise this level of cash, with the share price on its knees. "For the reason you raise in your next question, I’m afraid we cannot comment on future events at this time, I hope you’ll understand." AXA selling – Can you confirm that AXA have no insider knowledge of an imminent share placement as this would be deemed insider trading. “I confirm that we communicate with all shareholders simultaneously as is required of us by AIM rules and the UK-MAR legislation. AXA has no more information than any other shareholder.” Juvenescence deal – Could you please confirm that Juvenescence handing back the licence to SFX-01 was solely due to their own change of business direction, as opposed to any reasons relating to SFX-01 itself. And if possible, disclose the exact wording from Juvenescence. “Juvenescence returned the rights to us due to internal matters for them as we stated in the RNS at the time. As is best practice, the wording was agreed with them.” Is the bod exploring a possible listing of Nasdaq or is there any current takeover talks ongoing. “Again, as you’ll understand we can’t comment on future events but rest assured we are doing all we can to increase shareholder value in a difficult market for biotech companies. It may interest you to know that there are hundreds of Biotech companies on NASDAQ that are trading below cash. Further, Evgen is in the top 33% of all public European Biotech companies in terms of months of cash runway remaining according to a reputable London analyst group.” These responses disprove some of the nonsense that has been posted by certain people here, who are not invested but overly emotional and irrational. We have had a better end to the week than the start and I hope we have seen the last of AXA. Next week is looking promising for the start of the re-rate and I’m looking forward to receiving the news that will be coming out soon. |
Posted at 30/8/2023 22:38 by clocktower Just thought I would double check hat and took the following from the report:“ Share options may be granted under the LTIP as follows: ï An initial award to Executive Directors on joining the Company to support the recruitment and drive retention. ï An annual award to Executive Directors and other staff members to be made around the time of the AGM, though this may be deferred in the event of staff having inside information. Since 2021 vesting of share options has been subject to; a shareholder return metric (30%), delivery of strategic corporate objectives (40%), and time-vesting 3 years from grant (30%). The aims of this structure are to continue to align senior management remuneration with shareholder returns and to support staff retention. Achievement of the shareholder return metric depends on absolute share price performance. For the 2022/23 year grants, if the share price is between 8p and 38p (based on the non-volume weighted mean average price over the 3 months preceding the vesting date), options will vest on a straight-line basis between nil and 100% of the 30% shareholder return metric. The 2021/22 year grants are similarly assessed, save that the share price range is between 12p and 38p. Details of the awards can be seen on page 27. |
Posted at 26/7/2023 22:38 by clocktower Some of you were discussing the share options strike prices the other day, so I thought I would set out the figures from the last report.So I guess they will be doing everything in there power to reach these targets as some become exercisable from this October 2023. So impo these are so undervalued, with news due anytime, I expect them to rocket. "Since 2021 vesting of share options has been subject to; a shareholder return metric (30%), delivery of strategic corporate objectives (40%), and time-vesting 3 years from grant (30%). The aims of this structure are to continue to align senior management remuneration with shareholder returns and to support staff retention. Achievement of the shareholder return metric depends on absolute share price performance. For the 2022/23 year grants, if the share price is between 8p and 38p based on the non-volume weighted mean average price over the 3 months preceding the vesting date), options will vest on a straight-line basis between nil and 100% of the 30% shareholder return metric. The 2021/22 year grants are similarly assessed, save that the share price range is between 12p and 38p. Details of the awards together with outstanding options granted to the Executive Directors prior to Admission are set out in the Since 2021 vesting of share options has been subject to; a shareholder return metric (30%), delivery of strategic corporate objectives (40%), and time-vesting 3 years from grant (30%). The aims of this structure are to continue to align senior management remuneration with shareholder returns and to support staff retention. Achievement of the shareholder return metric depends on absolute share price performance. For the 2022/23 year grants, if the share price is between 8p and 38p (based on the non-volume weighted mean average price over the 3 months preceding the vesting date), options will vest on a straight-line basis between nil and 100% of the 30% shareholder return metric. The 2021/22 year grants are similarly assessed, save that the share price range is between 12p and 38p. Details of the awards together with outstanding options granted to the Executive Directors prior to Admission are set out in the table. Page 27. |
Posted at 19/6/2023 07:08 by manual dexterity Evgen Pharma PLC Grant Success for Glioblastoma studies19/06/2023 7:00am UK Regulatory (RNS & others) Evgen Pharma (LSE:EVG) Intraday Stock Chart Monday 19 June 2023 Click Here for more Evgen Pharma Charts. TIDMEVG RNS Number : 0732D Evgen Pharma PLC 19 June 2023 Evgen Pharma plc ("Evgen" or "the Company" or "the Group") Evgen receives notification of grant success in the Netherlands for Glioblastoma Pre-clinical and Clinical Studies Grant provides non-dilutive funding for SFX-01 in glioblastoma 19 June 2023 - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces that the Company's collaborator at The Erasmus University Medical Center, Rotterdam, NL has received a successful notice of a grant for Investigator Sponsored pre-clinical and clinical studies of SFX-01 in glioblastoma. The grant was awarded by KWF Dutch Cancer Society. The studies funded by the grant will cover use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study (ISS) window-of-opportunit Dr Huw Jones, CEO of Evgen Pharma said: "We announced earlier this year that our glioblastoma programme would be conducted as an ISS with non-dilutive funding. This award means that we remain on schedule to deliver this study in close collaboration with Dr Geurts. Congratulations to her and the Evgen team who compiled the grant application. The non-dilutive funding enables us to continue to preserve our capital and maintain our cash runway to the end of 2024 whilst continuing to generate valuable data on SFX-01. If the ISS and subsequent clinical trials succeed, SFX-01 will represent a novel and well tolerated option for patients with this devastating disease." Enquiries: Evgen Pharma plc Tel: +44 207 457 2020 Dr Huw Jones, CEO enquiries@evgen.com Richard Moulson, CFO FinnCap (Nominated Advisor and Tel: +44 20 7220 0500 Broker) Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane/Nigel Birks (ECM) Instinctif Partners Tel: +44 207 457 2020 Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.com / Adam Loudon |
Posted at 14/6/2023 18:52 by clocktower Kingalf you have been posting for a long time about EVG, almost exclusively I notice.The company raised £11million in 2021 at 8p before the deal with Stalicla was done, they have also achieved other milestones, including Evgen's new SFX-01 tablet formulation. This has all come at a cost. There has also been other collaborations, like that with Manchester Breast Centre, Collaboration with Università Sapienza di Roma etc. in 2022. We now have the share price at less than half of that but having achieved a great deal, with more news due before to long. When they raised £11 million, they could have raised a lot more because, applications under the Excess Application Facility cannot be satisfied in full, applications for New Ordinary Shares under the Excess Application Facility will be scaled back in accordance with the terms set out in the Circular. (RNS March 2021). The company has now done a lot of the important costly work and still has circa £5 million - I find it amazing that you do not consider the share to be worth less than 50% of the price money was raised at, with a deal in the bag that is due to bring in very substantial milestone payments - having already received around $500,000 As regards another raise, you can plug that, as one cannot see into the future, as if needed it could well be done at a Premium to the current share price because of performance and results. I know you predicted a raise before the last one but it does not follow that because of the share price fall, which might be because of the market forces in general or a number of holders seeing the opportunity to sell and finding the share price falling giving them the chance to buy back in for less money or buy more shares. In fact as you know Wololol only today stated he was waiting for the share price to fall further so he could buy back in having sold a short time ago. You also know that if the directors started buying in any decent volume or there was positive news (that could still be preventing them from do so), the share price would likely shoot up in a flash, and possible leading to anyone like W from missing the first boat, so to speak. Of course there is risk but unless you cannot afford to take risks, maybe it would be better to put your money in managed funds or remain in cash in National Savings if you want reasonable security but still watch inflation eat into your nest egg. Just spread your investments and only invest in any one, what you can afford to loose. Like I suggested to W take a look at TRX 54/55p if you want something with lower risk and I maybe wrong but I have invested in it several times before, riding the waves, and it is once again on the way up. So if your a trader and waiting to buy lower, good luck but I am invested and I have been and still am buying trading shares, that I have openly declared - so take your pick and do what you believe in but I have a very substantial holding that is in the RED at this time - unfortunately but that is the risk I accept. So do investors either go with you and W or with markth126 and OnTarget and myself etc and buy or hang around watching and either wanting each of us to loose a lot of money or missing out yourselves. In front of my desk I have a framed picture containing Rudyard Kipling's poem "IF" so I remember not to fear losses but learn from them when I do. “If” by Rudyard Kipling If you can keep your head when all about you Are losing theirs and blaming it on you, If you can trust yourself when all men doubt you, But make allowance for their doubting too; If you can wait and not be tired by waiting, Or being lied about, don’t deal in lies, Or being hated, don’t give way to hating, And yet don’t look too good, nor talk too wise: If you can dream—and not make dreams your master; If you can think—and not make thoughts your aim; If you can meet with Triumph and Disaster And treat those two impostors just the same; If you can bear to hear the truth you’ve spoken Twisted by knaves to make a trap for fools, Or watch the things you gave your life to, broken, And stoop and build ’em up with worn-out tools: If you can make one heap of all your winnings And risk it on one turn of pitch-and-toss, And lose, and start again at your beginnings And never breathe a word about your loss; If you can force your heart and nerve and sinew To serve your turn long after they are gone, And so hold on when there is nothing in you Except the Will which says to them: ‘Hold on!’ If you can talk with crowds and keep your virtue, Or walk with Kings—nor lose the common touch, If neither foes nor loving friends can hurt you, If all men count with you, but none too much; If you can fill the unforgiving minute With sixty seconds’ worth of distance run, Yours is the Earth and everything that’s in it, And—which is more—you’ " |
Posted at 09/6/2023 09:05 by clocktower Post 1688 - Rinse and repeat.However, I will respond to a point or two in your post, as a holder and buyer of the stock. I have not invested here because of Knight - he clearly has received advice or has knowledge of the potential here to have taken such a large stake, much in the same way as I have done in this case but I would not invest well over one million but if I had a billion I might, as I was advised by someone with very considerable knowledge in the field to take a look and research for myself, as SFX‐01 has huge potential. Fortunately for myself I started buying at sub 5p a very small amount, I added considerable more at around 3.4p - on the second spike, having bought some trading stock after the first spike, as I expected it go higher and was confident of another spike and I then bought trading stock and when it spiked again I then top sliced when it did. I have added even more with the profits I made from the trading stock as I consider the deals done make the share very undervalued. The accounts are what was expected, so nothing to get upset about there. I now have the largest stake in EVG that I have ever held. When it spikes again (and I expect it will on the next expected news or another deal) I will top slice again at around 8p and rinse and repeat buying more stock with profits on the dip after that, as I believe like markth126, that we will see this trading maybe up between 30/50p in time maybe more. Very large holders are usually kept pretty well informed but some do not want to be insiders, as it prevents them trading, so K certainly would not be shouting from the rooftops at a time like this, when everything is going to plan. The market in general is holding the share price down I guess, nothing else or less. If you are a disgruntled investor, having seen the share price fall so far, I quite understand your position but on the other hand if your trying to suggest K should do what you would like, then you have no hope, as I have not even contacted H Jones myself, as I believe he has done a good job and pulled off good deals. The timing is on track imo, you cannot force partners to run to your tune, as they have their own interests as I suspect you do - maybe wanting the share price even lower to buy in - if that is the case good luck but I am still a buyer, and I even mentioned I bought another 60k yesterday, and I was buying before the results. My only gripe is the way they awarded themselves nil paid options and did not announce the targets that were set, this I believe is out of order, as I have said before but as it is not in their interests to benefit until the share price is much higher, there is nothing to worry about there for the time being. It may also be taken over well before it hits the 30/50p range, which will be a pity for investors impo but I expect the take out price to be well above 10p if it is soon. DYOR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
